The European Commission announced that European Medicines Agency (EMA) headquarters has moved to Amsterdam, and I think the implications of Brexit haven’t fully shaken out yet.
The life science industry in general wants to understand when the UK will determine what they’re going to do in terms of honoring EU regulations, because there’s a lot of uncertainty there. Manufacturers should closely monitor further developments in the UK to anticipate any significant consequences for their business.
